SCOT Registry: Small Cell Lung Cancer Treatment and Outcome
- Registration Number
- NCT00997061
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC.
Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC.
Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Male or Female >/= 18 years
- Diagnosis of small cell lung cancer
- Patient newly diagnosed with SCLC
- Has given written informed consent (if applicable)
Exclusion Criteria
- Concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated in-situ carcinoma of the cervix.
- Patient presenting with recurrence of SCLC.
- Patients who has received any chemotherapy for the SCLC.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description HYCAMTIN HYCAMTIN -
- Primary Outcome Measures
Name Time Method Registry with disease, treatment and outcome data collected. 6-9mth recruitment period, 18mth study duration.
- Secondary Outcome Measures
Name Time Method survival rates 18 month period
Trial Locations
- Locations (1)
GSK Investigational Site
🇪🇸Zaragoza, Spain